AIM
AMEXAIM ImmunoTech Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$0.72-0.01 (-1.53%)
01:30 PM07:45 PM
News · 26 weeks55+140%
2025-12-072026-05-31
Mix2990d
- SEC Filings12(41%)
- Other11(38%)
- Insider4(14%)
- Offering2(7%)
Latest news
25 items- PRAIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical MilestonesOCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final subject, barring disqualifying pre-treatment circumstances. The final planned subject is scheduled for treatment in mid-June, surpassing the Company's original enrollment target of July 2026 in the Phase 2 clinical trial of AIM's drug Ampligen® (rintatolimod) combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the "DURIPANC" stud
- PRAIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency DeclarationPreviously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual Investor "Ebola: What This Means" Segment on June 4th at 9:00 AM ET OCALA, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced it will release an on-demand video presentation detailing important previously published pre-clinical findings supporting the potential role of its lead drug Ampligen® (rin
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form 424B5 filed by AIM ImmunoTech Inc.424B5 - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private PlacementOCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company", today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7,519,351 shares of common stock, par value $0.001 per share (the "Common Stock") (or common stock equivalents in lieu thereof) at a purchase price of $0.325 per share. The gross proceeds to the Company from the offering are expected to be approximately $2.4 million, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, the Company will issue and sell unregistered Series I
- SECSEC Form 424B5 filed by AIM ImmunoTech Inc.424B5 - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical PrioritiesOCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a significant increase in stockholder equity and that the Company has entered into Amendment #2 to its existing promissory note agreement with Streeterville Capital, LLC, extending the maturity date to June 30, 2027. AIM recently reported stockholder equity of approximately $2.1 million as of March 31, 2026, which is a significant increase of approximately $11.9 million in stockholder equity from the reported stockholder deficit of approximately $9.8 million as of December 31, 2025. The Company has also raised equity-generating funds through various transactions since Marc
- SECSEC Form 10-Q filed by AIM ImmunoTech Inc.10-Q - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form 8-K filed by AIM ImmunoTech Inc.8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic CancerPositive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon at Erasmus MC and an oncology consultant for AIM ImmunoTech, is now available on demand here OCALA, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that Professor Casper H.J. van Eijck, MD, PhD, Professor and Pancreato-biliary Surgeon at Erasmus Medical Center ("Erasmus MC") and a consultant for AIM, and AIM Chief Executive Officer Thomas K. Equels, MS, JD, participated in a Virtual Investor KOL Connect segment. The on-demand s
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross ProceedsOCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) ("AIM ImmunoTech" or the "Company"), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the Company and certain accredited investors to exercise certain outstanding Class A, Class B, Class C, Class D, Class E and Class F Warrants (the "Existing Warrants") to purchase up to an aggregate of 8,719,928 shares of common stock at a reduced exercise price of $0.48 per share for gross proceeds of approximately $4.2 million, before deducting placement agent fees and other estimated offering expenses. The Company intends t
- PRAIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination PotentialOCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the Final Primary Endpoint Report on Objective Response Rate data from a University of Pittsburgh Medical Center ("UPMC") Phase 2 clinical trial – in which AIM and Merck Sharp & Dohme ("Merck") are collaborators – evaluating Ampligen® (rintatolimod) in combination with checkpoint inhibition and chemotherapy in recurrent ovarian cancer—data that may signal a major step forward in overcoming resistance to immunotherapy. The study aimed to improve clinical outcomes by overcoming the immunosuppressive tumor microenvironment characteristic of ovarian cancer through locoregional
- PRAIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IPCompany to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today highlighted accelerating momentum in its pancreatic cancer program, underscored by Phase 3 trial planning underway, encouraging Phase 2 clinical signals, and a rapidly strengthening global regulatory and intellectual property ("IP") position. "The initiation of Phase 3 planning marks a critical step forward in our mission to bring Ampligen to patients with pancreatic cancer," said Thomas K. Equels, Chief Executive Officer of AIM. "With a growing body o
- PRAIM ImmunoTech Provides Routine Update on Annual FilingsOCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today advised that its audited consolidated financial statements for the fiscal year ended December 31, 2025, contained an audit report from its independent registered public accounting firm with a going concern emphasis of matter. Release of this information is required by Section 610(b) of the NYSE American Company Guide, and does not represent any change or amendment to any of the Company's filings for the fiscal year ended December 31, 2025. AIM management is confident in its continued ability to raise funds based on ongoing, promising results in the development of its lead drug, Am
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form 424B5 filed by AIM ImmunoTech Inc.424B5 - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech to Participate in Live Virtual Investor Closing Bell EventLive video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16th at 4:00 PM ET Register for the event here OCALA, Fla., April 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will participate in a Virtual Investor Closing Bell Event on Thursday, April 16, 2026, at 4:00 PM ET. Mr. Equels will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible
- SECSEC Form 10-K filed by AIM ImmunoTech Inc.10-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRBiotech Breakthroughs and Strategic Pivots Fuel Market MomentumDENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Today's action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. Artelo Biosciences (NASDAQ:ARTL) expands ART27.13's clinical footprint into ophthalmology through a fully funded investigator-initiated study agree
- PRAIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint InhibitorsOCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company's proprietary use of Ampligen (rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. The patent was granted in September 2025, but had to then pass a 6-month opposition period. Japan is one of the largest health markets in the world, with Japan and the United States expected to experience the greatest increase in global pancreatic cancer burden by 2030. The Japan patent expires December 20, 2039. The allowed claims in
- INSIDERCEO & President Equels Thomas K converted options into 25,000 shares, increasing direct ownership by 64% to 63,922 units (SEC Form 4)4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
- INSIDERDirector Chemerow David I. converted options into 25,000 shares, increasing direct ownership by 727% to 28,441 units (SEC Form 4)4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
AIM FAQ
5 questionsWhat does AIM ImmunoTech Inc. do?
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides...Where does AIM stock trade?
AIM ImmunoTech Inc. (AIM) is listed on AMEX.What sector and industry is AIM in?
AIM ImmunoTech Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to AIM?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare AIM side-by-side with any of them on Quantisnow.How can I track AIM on Quantisnow?
Quantisnow aggregates AIM ImmunoTech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AIM to receive live email and push alerts on every new disclosure.